story of the week
Very Low LDL-C Levels Achieved by Statin and Alirocumab Therapy Are Associated With Cardiovascular Risk Reduction
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Heart Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Eur Heart J 2023 Mar 05;[EPub Ahead of Print], GG Schwartz, M Szarek, DL Bhatt, VA Bittner, M Bujas-Bobanovic, R Diaz, S Fazio, Z Fras, SG Goodman, RA Harrington, JW Jukema, G Manvelian, R Pordy, KK Ray, M Scemama, HD White, PG StegFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.